OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and Chemotherapy-Resistant Metastatic Squamous NSCLC By Ogkologos - April 14, 2026 267 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the stage 1 of the phase III PRESERVE-003 study Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR College Basketball Star Plays First Game in Nearly Two Years After... December 1, 2020 FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer July 8, 2020 Pregnant Mom Experiencing Severe Leg And Back Pain Diagnosed With Stage... February 11, 2020 Opinion: What should the cancer agenda look like for the new... September 22, 2022 Load more HOT NEWS Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk... FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer... Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... New on NCI’s Websites for January 2020
